Product description
What is TB-500?
TB-500 is a synthetic peptide that is a functional analogue of naturally occurring thymosin beta-4 (Tβ4), a 43-amino acid polypeptide originally discovered in bovine thymus in 1981. TB-500 contains a key actin-binding sequence (LKKTETQ) responsible for the main biological effects of the parent protein, with N-terminal acetylation increasing stability.
Thymosin β4 is one of the most abundant intracellular proteins in mammals, occurring in high concentrations in all tissues except erythrocytes. Particularly high levels are found in platelets, leukocytes, wound fluid and macrophages - all elements involved in repair processes.
Mechanism of action
The basic mechanism of action of TB-500/Tβ4 is based on the regulation of actin dynamics and its consequences for cellular processes:
G-actin binding and sequestration – TB-500 binds with high affinity to monomeric G-actin (globular actin), forming a 1:1 complex. This binding prevents spontaneous polymerization of G-actin to F-actin (filamentous actin) and regulates the availability of monomers for controlled cytoskeletal remodeling. G-actin sequestration is crucial for cell migration, cell shape change and cell division.
Cell migration promotion – By regulating actin, TB-500 increases the ability of cells to migrate towards the site of damage. This effect affects many cell types: keratinocytes, fibroblasts, endothelial cells, myoblasts and stem/progenitor cells.
Stimulation of angiogenesis – TB-500 promotes the formation of new blood vessels by stimulating the migration of endothelial cells, creating capillary-like structures and increasing the density of microvessels in tissues. This mechanism is particularly important for the healing of tissues with poor vascularization (tendons, cartilage).
Anti-inflammatory effect – The sulfoxide form of thymosin β4 (Tβ4-SO) blocks neutrophil chemotaxis and has anti-inflammatory effects in vivo. TB-500 inhibits the release of pro-inflammatory cytokines and may modulate NF-κB activity.
Anti-apoptotic effect – TB-500 protects cells against apoptosis by increasing the expression of BCL-2 and reducing the activation of caspases, in part by preventing the release of cytochrome c from mitochondria.
Reduce Fibrosis – In wound healing processes, TB-500 reduces the number of myofibroblasts, which leads to less scar formation and fibrosis. This mechanism is important for maintaining the functionality of regenerated tissues.
Directions of scientific research
Thymosin β4 (and its synthetic analogue TB-500) is the subject of extensive preclinical research and limited clinical trials.
Wound healing research
The foundational study by Philp et al. (1999) showed that local or intraperitoneal administration of Tβ4 accelerated wound reepithelialization in rats by 42% after 4 days and up to 61% after 7 days compared to controls. Wounds treated with Tβ4 also showed increased narrowing (contraction), greater collagen deposition, and enhanced angiogenesis. In in vitro studies, Tβ4 stimulated keratinocyte migration 2-3 times at concentrations as low as 10 pg. These effects were confirmed in diabetic (db/db) and aged mice, where a 7-amino-acid synthetic peptide based on the actin-binding domain (TB-500 equivalent) promoted repair comparable to the full parent molecule.
Muscle regeneration research
Research by Hara et al. showed that Tβ4 acts as a chemoattractant for myoblasts (muscle precursor cells). Tβ4 and thymosin β10 mRNA levels are increased in the early stages of skeletal muscle regeneration in mice. Both Tβ4 and its sulfoxide form accelerated wound closure and increased chemotaxis of the C2C12 myoblastic line and primary myoblasts and myocytes derived from adult mouse muscle satellite cells.
Cardiac tests
Thymosin β4 is expressed in the developing heart and adult myocardium (endothelium, epicardium, coronary endothelium). Preclinical studies in models of myocardial infarction have shown:
- Improvement of left ventricular function
- Reduce infarct size
- Reduction of cardiomyocyte death
- Increase in the density of cardiac microvessels
- Improving long-term cardiac remodeling
The mechanism includes promotion of cardiac angiogenesis, reduction of inflammatory damage, and stimulation of cardiomyocyte survival pathways.
Ophthalmological examinations
Thymosin β4 is intensively studied in the context of corneal wound healing and Pseudomonas aeruginosa-induced keratitis. The peptide exerts anti-inflammatory effects by inhibiting NF-κB in corneal endothelial cells. Phase II clinical trials have been conducted with Tβ4 in corneal regeneration.
Sepsis research
In septic conditions, an increased level of free F-actin in the blood (F-actinemia) is observed, which can damage the endothelium and form microthrombi. Tβ4, as an actin-binding protein, inhibits F-actin polymerization and is being investigated as a potential protective factor in sepsis.
Dermatological tests - clinical trials
In Phase II clinical trials, Tβ4 (RGN-259, RegeneRx Biopharmaceuticals) promoted the healing of venous stasis ulcers and showed potential in the treatment of epidermolysis bullosa and other severe skin lesions.
Scientific context
TB-500/Thymosin β4 fits into the concept of "reminding adult organs of their embryonic state" - the peptide plays a key role in the embryonic development of the heart, brain, eyes and limbs, and its exogenous administration can reactivate regenerative processes in adult tissues.
Compared to other regenerative peptides:
- BPC-157 – gastric pentadecapeptide, stable in the gastric environment, acting mainly by modulating the NO system and the VEGFR2 pathway
- TB-500 – fragment of thymosin β4, acting by regulating actin and promoting cell migration, unstable in the gastric environment
These two peptides are often used together by researchers due to their complementary mechanisms of action - TB-500 promotes cell migration to the site of damage, BPC-157 supports angiogenesis and modulates signaling pathways.
Thymosin β4 and TB-500 are on the WADA Prohibited Substances List as agents that promote tissue regeneration and potentially improve athletic performance.
Research safety profile
In preclinical studies, thymosin β4 showed a favorable safety profile without significant toxic effects. Peptide is a natural component of the body, present in high concentrations in many tissues.
No serious adverse events related to therapy were reported in limited clinical studies (mainly dermatology and ophthalmology).
Potential theoretical concerns:
- The promotion of angiogenesis raises a theoretical question about the impact on the progression of malignant tumors, although there is no clinical evidence of an increased risk
- As an exogenous peptide, TB-500 may potentially induce immunogenic reactions
- The long-term safety profile of systemic administration in humans remains unknown
Bibliography - latest scientific research
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. PubMed
- Philp D, Nguyen M, Scheremeta B, et al. Thymosin beta4 increases hair growth by activation of hair follicle stem cells. FASEB J 2004;18(2):385-387. PubMed
- Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. PubMed
- Huff T, Müller CS, Otto AM, et al. Beta-thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol. 2001;33(3):205-220. PubMed
- Maar K, Hetenyi R, Maar S, et al. Utilizing Developmentally Essential Secreted Peptides Such as Thymosin Beta-4 to Remind the Adult Organs of Their Embryonic State—New Directions in Anti-Aging Regenerative Therapies. Cells. 2021;10(6):1343. PMC
- Ho ENM, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta(4), in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. PubMed
- Sosne G, Qiu P, Kurpakus-Wheater M. Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent. Clin Ophthalmol. 2007;1(3):201-207. PMC
- Philp D, Badamchian M, Scheremeta B, et al. Thymosin β4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003;11(1):19-24. PubMed
- Kleinman HK, Sosne G. Thymosin beta4 Promotes Dermal Healing. Vitam Horm. 2016;102:251-275. PubMed
- Rahaman KA, Muresan AR, Min H, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B 2024;1235:124033. PubMed
